Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume42.00K
Average Volume (3M)143.42K
Market Cap
C$8.97M
Enterprise ValueC$16.63M
Total Cash (Recent Filing)C$10.24K
Total Debt (Recent Filing)C$4.68M
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding598,186,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & R&D FocusPreveCeutical's focus on developing active pharmaceutical ingredients and multiple therapeutic programs creates a durable R&D platform. Owning APIs and early-stage assets enables future licensing, partnerships, or asset sales, providing multiple non-revenue value realization paths over months.
Novel Delivery TechnologyProprietary delivery approaches such as intranasal platforms are a structural competitive advantage: they can broaden indications, improve patient uptake, and be licensed independently of core therapeutics. Durable IP in delivery can create recurring partnership opportunities.
Lean Operational StructureA very small headcount implies low fixed overhead and operational flexibility, which can extend runway per financing round. For early-stage biotech, a lean team supports outsourcing R&D and tight cost control, helping preserve capital while advancing core programs.
Bears Say
No Commercial RevenueThe absence of any commercial revenue across multiple years means the company lacks product-market validation and must fund operations via external capital or partnerships. This structural lack of recurring sales raises execution and financing risk over the next several months.
Negative Equity & Rising DebtPersistently negative shareholders' equity combined with rising debt weakens financial flexibility and increases refinancing or covenant risk. For a pre-revenue biotech, this structurally limits access to non-dilutive capital and raises likelihood of dilutive financing or asset sales.
Accelerating Cash BurnMaterial deterioration in operating cash flow and persistent negative free cash flow indicate the company is consuming cash at an increasing pace. That entrenched burn profile shortens runway absent new funding and can force program delays or unfavorable financing choices.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$8.97M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Aug 20, 2026 which is in 5 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
Currently, no data Available
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 598,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―